Dashboard
Manage Tickers

JAGX Jaguar Health, Inc.

Nasdaq jaguar.health


$ 2.10 $ 0.00 (0 %)    

Tuesday, 14-Oct-2025 16:21:27 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 2.13
$ 2.12
$ 2.02 x 47
$ 2.16 x 100
$ 2.08 - $ 2.16
$ 1.57 - $ 33.25
90,983
na
4.63M
$ 2.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-24-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-22-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-17-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 04-03-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-21-2019 03-31-2019 10-Q
27 04-10-2019 12-31-2018 10-K
28 11-19-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 04-09-2018 12-31-2017 10-K
32 11-20-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 02-15-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-29-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/09/2025 21:06:16

jaguar-health-completes-meeting-with-us-food-and-drug-administration-for-potential-approval-to-treat-pediatric-indication-microvillus-inclusion-disease
Jaguar Health Completes Meeting With U.S. ...
10/06/2025 13:06:05

Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate f...

jaguar-health-files-for-resale-of-up-to-26m-shares-by-the-selling-stockholders
Jaguar Health Files For Resale Of Up To 2....
10/03/2025 20:20:37

-SEC Filing

jaguar-health-says-on-september-28-co-entered-securities-purchase-agreement-with-brown-stone-capital-limited-purchase-price-of-shares-is-156-per-share
Jaguar Health Says On September 28, Co Ent...
10/01/2025 20:22:47

On September 28, 2025, Jaguar Health, Inc. (the "Company") entered into a securities purchase agreement (the "Purch...

jaguar-health-receives-notice-of-250k-grant-from-fdas-center-for-veterinary-medicine-to-support-confirmatory-study-for-canalevia-ca1-for-chemotherapy-induced-diarrhea-in-dogs
Jaguar Health Receives Notice Of $250K Gra...
09/25/2025 13:05:21

Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, toda...

jaguar-healths-napo-pharma-submits-orphan-drug-application-to-fda-for-crofelemer-to-treat-diarrhea-in-metastatic-breast-cancer-patients-on-targeted-therapy
Jaguar Health's Napo Pharma Submits Orphan...
09/24/2025 13:04:48

Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant ...

jaguar-healths-canalevia-ca1-conditionally-fda-approved-for-canine-chemotherapy-induced-diarrhea-enrollment-has-reached-25-seeks-partnerships-to-expand-indication-to-general-diarrhea-in-dogs
Jaguar Health's Canalevia-CA1 Conditionall...
08/21/2025 13:05:57

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatm...

jaguar-healths-napo-pharmaceuticals-to-discuss-potential-regulatory-pathways-with-fda-regarding-crofelemer-for-ultrarare-pediatric-indication-microvillus-inclusion-disease
Jaguar Health's Napo Pharmaceuticals To Di...
08/19/2025 13:02:15

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/14/2025 17:06:18

jaguar-health-q2-2025-eps-1025-misses-713-estimate-sales-2979m-miss-3265m-estimate
Jaguar Health Q2 2025 EPS $(10.25) Misses ...
08/14/2025 12:04:42

Core News & Articles
Earnings Scheduled For August 14, 2025
08/14/2025 08:32:32

earnings-preview-for-jaguar-health
Earnings Preview For Jaguar Health
08/13/2025 18:03:30

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
07/14/2025 12:08:12

jaguar-health-announces-four-dogs-have-now-been-enrolled-in-ongoing-field-study-of-canalevia-ca1
Jaguar Health Announces Four Dogs Have Now...
07/10/2025 12:34:09

jaguar-healths-napo-announces-that-initial-proof-of-concept-results-from-ongoing-iit-show-liquid-formulation-of-crofelemer-reduced-required-tpn-and-supplementary-intravenous-fluids-in-third-intestinal-failure-patient
Jaguar Health's Napo Announces That Initia...
06/30/2025 13:23:19

As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer re...

jaguar-health-and-napo-therapeutics-announce-initial-proof-of-concept-results-showing-liquid-formulation-of-crofelemer-reduced-total-parenteral-nutrition-in-third-intestinal-failure-orphan-disease-patient
Jaguar Health And Napo therapeutics Announ...
06/30/2025 13:21:01

jaguar-health-board-unanimously-authorizes-company-to-include-cryptocurrency-as-treasury-reserve-asset
Jaguar Health Board Unanimously Authorizes...
06/26/2025 13:04:24

jaguar-health-pursues-eu-approval-for-canalevia-to-treat-general-dog-diarrhea
Jaguar Health Pursues EU Approval For Cana...
06/25/2025 13:03:43

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatme...

jaguar-health-announces-maturity-date-has-been-extended-from-june-30-2025-to-january-30-2026-for-257m-aggregate-principal-amount-of-convertible-promissory-notes-originally-issued-by-company-as-part-of-previously-announced-3448m-bridge-financing
Jaguar Health Announces Maturity Date Has ...
06/24/2025 20:17:35

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that the maturity date has been ...

jaguar-health-updates-on-orphan-disease-intestinal-failure-program-completion-of-napos-phase-2-study-of-crofelemer-in-pediatric-mvid-patients-is-expected-in-mid-2026-as-planned
Jaguar Health Updates On Orphan Disease In...
06/23/2025 13:07:22

Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for micro...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION